Sunita Nathan

List of Publications by Year
in descending order

68	1,121	393982	454577
papers	citations	19 h-index	30 g-index

75	75	75	1755
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica, 2023, 108, 150-160.	1.7	10
2	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847.	2.5	5
3	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	2.5	35
4	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 31-37.	1.3	4
5	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 335.e1-335.e17.	0.6	5
6	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	3.4	32
7	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplantation, 2022, 57, 1150-1163.	1.3	2
8	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995.	2.5	5
9	Transplantation provides superior survival high risk myeloid malignancies in older patients. Leukemia and Lymphoma, 2022, 63, 2494-2498.	0.6	1
10	Coreâ€binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	0.7	6
11	Role of Physical Activity and CardiacÂRehabilitation in Patients UndergoingÂHematopoietic StemÂCellÂTransplantation. JACC: CardioOncology, 2021, 3, 17-34.	1.7	15
12	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683.	3.3	45
13	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	0.6	85
14	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Advances, 2021, 5, 1648-1659.	2.5	28
15	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	1.3	6
16	Human Herpesvirus-6 Infection and Calcineurin Inhibitor Pain Syndrome Interaction after Umbilical Cord Blood Transplant. Transplantation and Cellular Therapy, 2021, 27, 439-440.	0.6	0
17	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2021, 27, 679.e1-679.e8.	0.6	10
18	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	0.6	11

#	Article	IF	Citations
19	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	0.6	15
20	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphomaâ€“type Richter syndrome. Blood Advances, 2021, 5, 3528-3539.	2.5	24
21	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077.	1.3	13
22	Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis. Blood, 2021, 138, 907-907.	0.6	0
23	The Impact of Non-Clinical Factors in Clinical Trial Enrollments of Patients with Hematologic Malignancies. Blood, 2021, 138, 1914-1914.	0.6	0
24	Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. Bone Marrow Transplantation, 2020, 55, 833-835.	1.3	0
25	Outcomes in patients with aggressive Bâ€cell nonâ€Hodgkin lymphoma after intensive frontline treatment failure. Cancer, 2020, 126, 293-303.	2.0	18
26	DLBCL After Allogeneic HCT in a Patient With Transformed DLBCL: Does It Matter Whether Relapse or PTLD?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 264-266.	0.2	0
27	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	2.5	18
28	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist, 2020, 25, 878-885.	1.9	28
29	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
30	Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2020, 61, 2008-2011.	0.6	1
31	Calcineurin-inhibitor induced pain syndrome after stem cell transplant. Leukemia and Lymphoma, 2020, 61, 2230-2233.	0.6	2
32	Checkpoint blockade treatment sensitises relapsed/refractory nonâ€Hodgkin lymphoma to subsequent therapy. British Journal of Haematology, 2020, 191, 44-51.	1.2	19
33	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	2.5	63
34	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica, 2020, 105, 1329-1338.	1.7	23
35	Biosimilar infliximab administration for the management of acute graft-versus-host disease. Journal of Oncology Pharmacy Practice, 2020, 26, 2047-2051.	0.5	0
36	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Advances, 2020, 4, 2317-2324.	2.5	1

#	Article	IF	Citations
37	Successful Triplet Pregnancy Post-Allogeneic Stem Cell Transplant in a Patient With Doxorubicin-Induced Cardiomyopathy. JACC: Case Reports, 2020, 2, 987-990.	0.3	2
38	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biology of Blood and Marrow Transplantation, 2020, 26, 1137-1143.	2.0	13
39	Impact of type of reducedâ€intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. British Journal of Haematology, 2020, 190, 573-582.	1.2	19
40	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Advances, 2020, 4, 983-992.	2.5	34
41	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist, 2020, 25, e993-e997.	1.9	7
42	Outcomes of rituximabâ€BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 2020, 126, 2279-2287.	2.0	17
43	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. Blood, 2020, 136, 15-16.	0.6	0
44	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	3.2	10
45	Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies. Infectious Disease Clinics of North America, 2019, 33, 331-359.	1.9	12
46	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	2.5	89
47	Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation. Journal of Clinical Medicine, 2019, 8, 1968.	1.0	23
48	Allogeneic transplantation in elderly patients â‰¥65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer Journal, 2019, 9, 97.	2.8	11
49	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e46-e54.	2.0	24
50	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. Journal of Hematology and Oncology, 2019, 12, 6.	6.9	29
51	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 648-661.	1.3	14
52	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 662-673.	1.3	48
53	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e145-e154.	2.0	16
54	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biology of Blood and Marrow Transplantation, 2018, 24, 486-493.	2.0	3

#	Article	IF	Citations
55	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	2.5	35
56	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. Blood, 2018, 132, 453-453.	0.6	1
57	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 1626-1626.	0.6	7
58	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 93-93.	0.6	0
59	Impact of cachexia on outcomes in aggressive lymphomas. Annals of Hematology, 2017, 96, 951-956.	0.8	30
60	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. British Journal of Haematology, 2016, 174, 235-248.	1.2	115
61	Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. Therapeutic Advances in Hematology, 2014, 5, 139-152.	1.1	13
62	Transforming growth factor-beta gene polymorphisms and acute graft-versus-host disease.. Journal of Clinical Oncology, 2013, 31, e18013-e18013.	0.8	0
63	Secondary neutropenia (SN) after autologous hematopoietic stem cell transplantation (AHSCT) in patients (pts) with lymphoma.. Journal of Clinical Oncology, 2012, 30, 6552-6552.	0.8	0
64	Engraftment Kinetics After Alimtuzumab-Based Allogeneic Stem Cell Transplant (SCT): Full Donor T-Cell Chimerism Did Not Predict for Acute Graft Versus Host Disease (GVHD) or CMV Reactivation. Blood, 2012, 120, 4162-4162.	0.6	0
65	Efficacy of Plerixafor Administered At 5:00PM for Stem Cell Mobilization in Lymphoma and Myeloma Patients Undergoing Autologous Stem Cell Transplant,. Blood, 2011, 118, 4061-4061.	0.6	0
66	A Long-Term Follow-up Report on Autologous Hematopoetic Cell Transplant (AuHCT) for Patients with Hodgkin Lymphoma â€" Limited Utility of Post-Transplant Surveillance Computerized Axial Tomography (CAT scan) and/or PET Scan,. Blood, 2011, 118, 4205-4205.	0.6	0
67	The Transplant Outcomes of a 10/10 Matched Unrelated Donor (MUD) Stem Cell Transplant (SCT) Is Similar to a HLA Identical Related Donor (RD) Transplant.. Blood, 2009, 114, 4346-4346.	0.6	0
68	Efficacy of Administration of Plerixafor (MozobilÂ®) at 5:00 PM for Stem Cell Mobilization (SCM) in Patients Receiving Autologous Stem Cell Transplant.. Blood, 2009, 114, 3218-3218.	0.6	2